Back to Peptide Index

IGF-1 LR3

MuscleEvidence Level: researchNot FDA-approved for general therapeutic use; available for research purposes only.
Peptide #14

IGF-1 LR3 is a modified, synthetic version of insulin-like growth factor-1 (IGF-1), specifically designed with an extended half-life to enhance its potency and bioavailability. Known primarily for its powerful anabolic properties, IGF-1 LR3 significantly stimulates muscle growth, cellular proliferation, and differentiation, making it highly appealing in bodybuilding, sports performance, and therapeutic contexts related to muscle-wasting diseases. Unlike naturally occurring IGF-1, the LR3 variant is less prone to degradation, enabling prolonged metabolic activity and amplified biological effects, including increased lean muscle mass, enhanced tissue regeneration, and improved recovery from injuries. In addition to muscle-related benefits, IGF-1 LR3 positively impacts metabolism by improving insulin sensitivity, glucose metabolism, and nutrient uptake, suggesting its potential role in managing metabolic disorders such as diabetes or obesity.

Alternative Names:

Insulin-like Growth Factor 1 Long Arg3

Overview

IGF-1 LR3 is a modified, synthetic version of insulin-like growth factor-1 (IGF-1), specifically designed with an extended half-life to enhance its potency and bioavailability. Known primarily for its powerful anabolic properties, IGF-1 LR3 significantly stimulates muscle growth, cellular proliferation, and differentiation, making it highly appealing in bodybuilding, sports performance, and therapeutic contexts related to muscle-wasting diseases.

How It Works

IGF-1 LR3 promotes muscle growth by stimulating the proliferation and differentiation of muscle cells (myocytes), enhancing protein synthesis, and increasing muscle mass and strength. It activates satellite cells essential for muscle repair and regeneration, supports faster recovery, and improves muscle hypertrophy. It also enhances insulin sensitivity and glucose metabolism, improving energy utilization and nutrient uptake.

Clinical Effects

Significant muscle growth, enhanced tissue regeneration, improved recovery from injuries, improved insulin sensitivity, glucose metabolism, and nutrient uptake.

Therapeutic Applications

Muscle growth, tissue repair, metabolic regulation, muscle-wasting conditions, sarcopenia, athletic performance enhancement, anti-aging.

Research Studies

Clinical Trials

Human trials are limited; preliminary data is promising but extensive research is required.

Preclinical Studies

Animal studies demonstrate significant increases in muscle mass, strength, and function.

Frequently Asked Questions

Is IGF-1 LR3 legally available? Yes, IGF-1 LR3 is legally available for research purposes from specialized suppliers but is not approved for general therapeutic use. Have human trials been conducted with IGF-1 LR3? Human trials are limited, and while preliminary data is promising, extensive research is required to confirm its long-term safety and efficacy. What are potential side effects of IGF-1 LR3? Reported side effects in preclinical studies include hypoglycemia, swelling, and injection site reactions. Comprehensive human studies are necessary to thoroughly assess safety. How is IGF-1 LR3 typically administered? IGF-1 LR3 is commonly administered via subcutaneous injections in research settings, with dosages and protocols carefully tailored to specific experimental objectives. Can IGF-1 LR3 be combined with other peptides or performance enhancers? While frequently combined in experimental protocols, interactions between IGF-1 LR3 and other substances require cautious, controlled study to ensure safety and efficacy. Does IGF-1 LR3 cause permanent muscle gains? IGF-1 LR3 promotes significant muscle gains during administration. However, maintaining these gains long-term typically requires continued training or periodic administration.

Quick Information

Half-Life:

Extended half-life due to reduced binding affinity for IGF-binding proteins.

Bioavailability:

Enhanced bioavailability due to reduced binding affinity for IGF-binding proteins.

Metabolism:

Less prone to degradation, enabling prolonged metabolic activity.

Safety Information

Safety Profile

Comprehensive human studies are necessary to thoroughly assess safety.

Contraindications

Side Effects: Reported side effects in preclinical studies include hypoglycemia, swelling, and injection site reactions. Safety Profile: Comprehensive human studies are necessary to thoroughly assess safety.

Side Effects

Reported side effects in preclinical studies include hypoglycemia, swelling, and injection site reactions.

Research References

Adams, G.R. (2002). Autocrine/paracrine IGF-I and skeletal muscle adaptation. Journal of Applied Physiology. Barton, E.R. (2006). The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Applied Physiology, Nutrition, and Metabolism. Velloso, C.P. (2008). Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology.

Additional Resources